Italia markets closed

HTG Molecular Diagnostics, Inc. (HTGM)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
5,51+0,42 (+8,25%)
Al 1:35PM EST. Mercato aperto.

HTG Molecular Diagnostics, Inc.

3430 East Global Loop
Tucson, AZ 85706
United States
877 289 2615
http://www.htgmolecular.com

Settore/iHealthcare
SettoreDiagnostics & Research
Impiegati a tempo pieno108

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Timothy B. JohnsonExec. Chairman212,35kN/D1961
Mr. John L. LubniewskiPres, CEO & Director384,87kN/D1964
Mr. Shaun D. McMeansSr. VP of Fin. & Admin., CFO, Sec. and Treasurer321,37kN/D1962
Ms. Laura Lee GodlewskiVP of Fin. & Principal Accounting OfficerN/DN/D1980
Dr. Maureen T. CroninSr. VP & Chief Scientific OfficerN/DN/D1953
Dr. Debra A. GordonSr. VP & Chief Legal CounselN/DN/D1960
Mr. Sam M. Rua Jr.Sr. VP of Regulatory Affairs & Quality SystemsN/DN/D1960
Dr. Patrick C. RocheSr. VP of R&DN/DN/D1953
Mr. Byron T. LawsonSr. VP & Chief Commercial OfficerN/DN/D1975
Laura BeggrowPres of DiagnosticsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq path assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq ALKPlus assay EU;HTG EdgeSeq precision immuno-oncology panel; HTG lung fusions assay; HTG autoimmune panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Governance aziendale

L'ISS Governance QualityScore di HTG Molecular Diagnostics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.